Results 241 to 250 of about 147,603 (376)

Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia‐Induced Glycolysis by Targeting Hypoxia‐Inducible Factor‐1 Alpha and Downstream Metabolites

open access: yesCancer Medicine, Volume 15, Issue 1, January 2026.
The debate in the field of cancer immunotherapy is being changed as nanotechnology breaks the obstacle of cancer immune evasion, target delivery, and systemic toxicity. Esthetically advanced methods that are discussed in this review are nanovaccine, nanoparticle‐enabled checkpoint barrier, cytokine delivery, and T‐cell modulation techniques that ...
Daniel Ejim Uti   +7 more
wiley   +1 more source

A Whiff of Garlic, a Turn of Fate: Recognizing Organophosphorus Poisoning Amid Diagnostic Uncertainty: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT OP compounds, commonly used as pesticides, are readily available over the counter and frequently implicated in intentional poisoning. We report a case of a 43‐year‐old male with OP poisoning initially misdiagnosed as alcohol intoxication. He was intubated in the emergency department on arrival due to a low Glasgow Coma Scale (GCS) of 6/15 and ...
Sujan Tamang   +6 more
wiley   +1 more source

Anxiety Symptoms Before and After Single-Incision Mini-Sling Surgery in Women With Stress Urinary Incontinence: A Prospective Study. [PDF]

open access: yesCureus
Despoina D   +7 more
europepmc   +1 more source

Lifetime Risk of Stress Urinary Incontinence or Pelvic Organ Prolapse Surgery

open access: yesObstetrics and Gynecology, 2014
Jennifer M Wu   +4 more
semanticscholar   +1 more source

Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Eosinophilic fasciitis (EF) is a rare condition with an unknown cause. This case study showed that a 40‐year‐old man with EF did not respond to standard treatments but improved after receiving rituximab and intravenous immunoglobulin (IVIG). Further studies are needed to confirm rituximab's effectiveness and long‐term safety for EF.
Maryam Sahebari   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy